SOTIO is a Czech biotechnology company developing therapies for the treatment of cancer and autoimmune diseases. Preeminent scientists from the Czech Republic work at SOTIO’s world-class research facility in Prague where the company has been developing its own platform of active cellular immunotherapy based on dendritic cells. SOTIO aims to better understand the role of dendritic cells in the therapeutic activation of the body’s immune response and is verifying the safety and efficacy of their use for patient treatment in clinical trials. The company’s product portfolio under development currently includes therapies for the treatment of prostate, ovarian and lung cancer. The company’s own scientific team is also researching the possibilities of treating other types of cancer and autoimmune diseases. SOTIO’s laboratories are among the largest and most modern of their kind in Europe and meet GMP international standards. SOTIO closely cooperates with the Institute of Immunology of the 2nd Medical Faculty of Charles University and with the Motol University Hospital in Prague. It is also an active supporter of Czech-Chinese relations in the medical field, and has been forging links between Czech and Chinese scientists and leading physicians based on common research projects. In June 2014, an opening of the company’s own laboratories meeting GMP standard took place in Beijing. These laboratories are servicing joint scientific research projects with leading Chinese hospitals, producing therapies for treating Chinese patients with lung and prostate cancer. The successful collaboration will help to create many new high qualified jobs and a new basis for further common scientific research and development. SOTIO is part of the PPF Group and is active in Europe, China, the US and Russia, employing more than 300 professionals. SOTIO is part of the PPF Group and is active in Europe, China, the US and Russia, employing more than 300 professionals.